Company Encyclopedia
View More
name
Rallybio
RLYB.US
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
1.930 T
RLYB.USMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking155/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-21.17%E
    • Profit Margin-2102.37%E
    • Gross Margin-135.85%E
  • Growth ScoreB
    • Revenue YoY12.71%B
    • Net Profit YoY78.84%A
    • Total Assets YoY-14.36%E
    • Net Assets YoY-10.99%D
  • Cash ScoreC
    • Cash Flow Margin-4.76%D
    • OCF YoY12.71%B
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio6.84%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

    Several biotech stocks saw significant price increases in after-hours trading, driven by data releases and earnings reports. InflaRx N.V. (IFRX) surged 63.41% to $2.01, Rallybio Corp. (RLYB) rose 12.84% to $0.71, and FibroBiologics Inc. (FBLG) climbed 13.51% to $0.40. AbCellera Biologics Inc. (ABCL) advanced 6.51% to $4.16, while BioRestorative Therapies Inc. (BRTX) gained 11.68% to $1.53. Cellectis S.A. (CLLS) increased 6.58% to $3.40, reporting a net income of $589 thousand.

    rttnews·
    US
    RLYB
    -0.72%
    US
    FBLG
    +1.42%
    US
    CLLS
    -1.86%
    rttnews·
    US
    RLYB
    -0.72%
    US
    FBLG
    +1.42%
    US
    CLLS
    -1.86%

    Rallybio Corp SEC 10-Q Report

    Rallybio Corp has released its Q2 2025 Form 10-Q report, highlighting a total revenue of $0.2 million, a decrease from 2024, but a net income of $16.0 million, a significant improvement from a loss in the previous year. Key developments include the initiation of a PK/PD study for RLYB116, the discontinuation of the RLYB212 program, and a strategic alliance with AbCellera. The company also sold its interest in REV102 to Recursion Pharmaceuticals for $20 million. Future plans focus on hematologic conditions and collaboration with Johnson & Johnson.

    TradingView·
    US
    RLYB
    -0.72%
    TradingView·
    US
    RLYB
    -0.72%

    Rallybio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 212 K

    LB filings·
    US
    RLYB
    -0.72%
    LB filings·
    US
    RLYB
    -0.72%

    Rallybio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 212 K

    LB filings·
    US
    RLYB
    -0.72%
    LB filings·
    US
    RLYB
    -0.72%

    Rallybio posts Q3 net income of $16 million

    Rallybio Corporation reported a Q3 net income of $16 million, or $0.36 per share, a turnaround from a net loss of $11.5 million in Q3 2024. As of September 30, 2025, the company had $59.3 million in cash and marketable securities. Rallybio generated $20 million from selling its interest in REV102 to Recursion Pharmaceuticals and advanced its lead program, RLYB116, completing dosing in Cohort 1 of its Phase 1 study, with data from Cohort 2 expected in Q4 2025.

    Reuters·
    US
    RLYB
    -0.72%
    Reuters·
    US
    RLYB
    -0.72%
    © 2025 Longbridge｜Disclaimer